Log In
BCIQ
Print this Print this
 

NOV120501

  Manage Alerts
Collapse Summary General Information
Company National OncoVenture
DescriptionUndisclosed
Molecular Target BCR-ABL tyrosine kinase (BCR-ABL)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationChronic myelogenous leukemia (CML)
Indication DetailsTreat chronic myelogenous leukemia (CML)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today